ClinicalTrials.gg
CompletedNCT06182267Updated Jan 2, 2024

Maximal Use Study to Determine the Pharmacokinetics of L-arginine After Exaggerated Oral Use of COL101

A Phase 1 interventional study of L Arginine and Sodium Fluoride in Caries,Dental, sponsored by Colgate Palmolive. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-02.

Sponsored by Colgate Palmolive · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Dental Caries with a site in United States — 16 open to participants now, 19 under way, 3 of them phase 3. Dental Caries · United States.

Enrollment
135th of 168
29 · median 60
Started
2023
with 6 others
Phase 1
13 of 193
none open now
Registered
166th of 193
by date

Among the 193 studies in Dental Caries with a site in United States, this one is the 135th largest by enrollment of the 168 interventional ones that give a count, is one of 7 that started in 2023, is one of 13 in phase 1, and was the 166th registered.

Dental Caries

1,174 studies on the registry are indexed under Dental Caries; 209 are open to participants now.

Browse Dental Caries studies →

Open to participants now

16 of the 193 studies in Dental Caries with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Dental Caries with a site in United States, or all of them as a file.
02

Study summary

Pharmacokinetic (PK) study of L-arginine after exaggerated oral use of the novel dentifrice product COL101 after repeated daily applications in healthy adult subjects.

03

Conditions studied

  • Caries,Dental

Browse trials for

Keywords

  • arginine
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 - 65 years of age;
  • In good health as determined by medical history, physical and dental examination, vital signs and clinical laboratory safety assessment;
  • Agree to delay any elective dentistry including dental prophylaxis until the study has been completed;
  • Agree to refrain from supplements containing arginine throughout the duration of the study;
  • In the case of females of (unless surgically sterilized [hysterectomy, bilateral oophorectomy, tubal ligation] or are for at least 12 months), are using one acceptable form of (oral/implant/injectable/transdermal contraceptives, intrauterine device (IUD), condom with spermicide, diaphragm with spermicide, partner's vasectomy). Abstinence or vasectomies are acceptable if the female subject agrees to implement an acceptable form of birth control if her lifestyle/partner changes;
  • For females of childbearing potential, have a negative serum pregnancy test (SPT) at the Screening visit and a negative urine pregnancy test (UPT) on Day -2 prior to randomization, and agree to submit to a SPT at the end of study (EOS) visit;
  • Are free of any systemic or dermatologic disorder, which, in the opinion of the Principal Investigator (PI), will interfere with the study results or increase the risk of adverse events (AEs); and
  • Read, understand, and provide signed .

Exclusion criteria

Exclusion Criteria:

  • A female who is pregnant, plans to become pregnant during the study, or is breastfeeding a child;
  • Are actively being treated for periodontitis, gingivitis or caries;
  • Have severe periodontal disease, as characterized by purulent exudates, generalized mobility, or severe recession;
  • Any central nervous system, cardiac, pulmonary, renal, gastrointestinal (GI), endocrinological, respiratory, or metabolic conditions (or history), or other pathological or physiological conditions, that might interfere with the study results in the investigator's opinion;
  • Any condition which, in the investigator's opinion, puts the subject at significant risk, could confound the study results, or may interfere significantly with the subject's participation in the study;
  • Have known or suspected allergies to oral care products, toothpaste, or ingredients in toothpaste;
  • Immunization within 10 days of Day 1;
  • Anticipated need for surgery or hospitalization during the study;
  • Consumed alcohol within 48 hours prior to Day 1 or refuses to abstain from alcohol throughout the duration of the study;
  • History of heavy smoking (i.e., more than 10 cigarettes a day or the tobacco/nicotine equivalent) within 3 months of screening or refuses to abstain from tobacco or nicotine-containing products throughout the duration of the study;
  • Consumed caffeine (i.e., coffee, tea, caffeinated soda, chocolate) within 48 hours prior to Day 1 or refuses to abstain from caffeine throughout the duration of the study;
  • Donation or loss of blood (excluding volume drawn at screening) of ≥ 450 mL within 3 months of Day 1;
  • Active or lifetime infection (e.g., negative test for (HIV) and hepatitis, and no history of tuberculosis and syphilis) or a history of severe infection during the 30 days prior to screening;
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment;
  • Is unwilling or unable to refrain from using prescription medications for 30 days prior to Day 1 or over the counter medications, herbal preparations, and supplements for 14 days prior to Day 1 (excluding permitted forms of and occasional use of acetaminophen [up to 2 g in 24 hours]);
  • Inability or unlikeliness of the subject to comply with the dose schedule and study evaluations, in the opinion of the investigator;
  • Is currently participating in any clinical trial;
  • Has received any drug(s) within 30 days or 5 half-lives, whichever is longer, prior to study Day 1;
  • Any condition that would, in the investigator's judgment, interfere with full participation in the study, including attending required study visits; pose a significant risk to the subject; or interfere with interpretation of study data;
  • Inability of the subject (or legally authorized representative) to comprehend the electronic form (eICF) or unwillingness to sign the eICF; and/or
  • Subject meets eligibility criteria, but study is filled
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Group I

    toothpaste containing 8% L-arginine

    Drug: L Arginine · Drug: Sodium Fluoride

  • Active comparator
    Group II

    toothpaste containing 0.24% sodium fluoride

    Drug: L Arginine · Drug: Sodium Fluoride

Interventions

06

What researchers measure

Primary outcomes

  1. Arginine in blood

    Measurement of arginine in blood after oral brushing

    Time frame: Day 1 for 24 hours

  2. Arginine in blood

    Measurement of arginine in blood after oral brushing

    Time frame: Day 7 for 24 hours

  3. Arginine in blood

    Measurement of arginine in blood after oral brushing

    Time frame: Day 10 for 24 hours

  4. Arginine in blood

    Measurement of arginine in blood after oral brushing

    Time frame: Day 16 for 24 hours

07

Study locations

1 site
  • TKL Research, Inc
    Fair Lawn, New Jersey 07410, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2023, 0 months.

Of 15 phase 1 interventional studies under Dental Caries, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 18. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2023
First posted
Dec 26, 2023
StartActual
Nov 27, 2023
Primary completionActual
Dec 22, 2023
CompletionActual
Dec 22, 2023
Last update
Jan 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06182267
Lead sponsor
Colgate Palmolive
Responsible party
Sponsor
First posted
Dec 26, 2023
Start date
Nov 27, 2023
Primary completion
Dec 22, 2023
Completion
Dec 22, 2023
Last update
Jan 2, 2024

Study contacts

Irina Krause, RN, MSN
study director · TKL

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arginine

Start the discussion